Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial

Mengmei Wang†, Yang Zhao†, Weihua, Hu†, Dong Zhao†, Yunting Zhang†, Tao Wang†, Zhishui Zheng†, Xiaochen Li†, Shaolin Zeng†, Zhenlian Liu‡, Li Lu‡, Zhihui Wan‡, Ke Hu*†

1 Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Zhangzhidong Road No. 99, Wuhan 430060, China.

2 East Campus, Renmin Hospital of Wuhan University, No. 17, Gaoxin 6th Road, Donghu High-tech District, Wuhan, China.

* Corresponding author. Address correspondence and reprint requests to Dr. Ke Hu (E-mail: huke-rmhospital@163.com, Tel: 86-27-27-88041911-82215. Fax: 86-27-88042292).

† These authors contributed equally to this work.

summary

Leflunomide has inhibitory efficacy on SARS-CoV-2 replication in vitro. However, our data show that it did not shorten the number of virus clearance days or shorten the duration of stay in the hospital for COVID-19 patients with prolonged post-symptomatic shedding.
Abstract

**Objective:** To evaluate the efficacy and safety of leflunomide, an approved dihydroorotate dehydrogenase inhibitor, to treat COVID-19 patients with prolonged post-symptomatic viral shedding.

**Methods:** We conducted a prospective, randomized, controlled, open-label trial involving hospitalized adult COVID-19 patients with prolonged PCR positivity. Patients were randomly assigned to receive either leflunomide (50 mg, q12h, three consecutive times, orally; then 20 mg, once daily for 8 days), in addition to nebulized interferon alpha 2a (IFN α-2a, 3 million IU each time, twice daily for 10 days), or nebulized IFN α-2a alone for 10 days. The primary end point was the duration of viral shedding.

**Results:** A total of 50 COVID-19 patients with prolonged PCR positivity were randomized into 2 groups; 26 were assigned to the leflunomide group, and 24 were assigned to the interferon alone group. Treatment with leflunomide was not associated with a difference from the interferon alone group in the duration of viral shedding (hazard ratio for negative RT-PCR, 0.70; 95% confidence interval, 0.391-1.256; \( P = 0.186 \)). In addition, the patients given leflunomide did not have a substantially shorter length of hospital stay than patients treated with interferon alone, with median (IQRs) durations of 29.0 (19.3-47.3) days and 33.0 (29.3-42.8) days, respectively, \( P = 0.170 \). Two leflunomide recipients were unable to complete the full 10-day course of administration due to adverse events.

**Conclusions:** In COVID-19 patients with prolonged PCR positivity, no benefit in terms of the duration of viral shedding was observed with the combined treatment of leflunomide and IFN α-2a beyond IFN α-2a alone.

**Key words:** COVID-19; SARS-CoV-2; leflunomide; interferon alpha 2a; viral shedding
INTRODUCTION

Although clinical trials of compassionate or off-label uses of several drugs have been conducted, there is no specific and effective medication to treat patients with COVID-19 [1,2,3]. Partial clinical trial results of lopinavir-ritonavir, remdesivir, chloroquine and hydroxychloroquine have already been performed in different countries, but have shown only moderate and controversial effects [2, 4]. Therefore, it is still necessary to seek safe and solid strategies to treat COVID-19 when facing the increasing number of patients worldwide [5].

The pandemic of COVID-19 has been under control in Wuhan, China since March, 2020, but some patients remained viral RNA-positive after their symptoms had resolved and their abnormal CT imaging had improved significantly [6, 7, 8]. Long-term COVID-19 positive patients cause many problems [9], for example, they have to stay in the hospital for a long time and require more medical resources. In addition, they often had psychological disorders. Moreover, no specific therapeutic agents have been recommended for COVID-19 patients with prolonged post-symptomatic shedding [10], which has become a great concern [11].

Acute RNA virus replication, including SARS-CoV-2, largely depends on intracellular pyrimidine resources, and antagonists of dihydroorotate dehydrogenase (DHODH), a rate-limiting enzyme in the fourth step of the de novo pyrimidine biosynthesis pathway, can efficiently prohibit viral genome replication in infected cells [12]. Leflunomide, an approved DHODH inhibitor, has been widely used to treat patients with autoimmune diseases [13], but whether leflunomide can be used to treat COVID-19 patients is unknown. As COVID-19 patients also suffer from excessive inflammations similar to autoimmune patients [14], leflunomide may benefit COVID-19 patients through its antiviral and antiinflammation effects. A small-scale study of leflunomide treatment for confirmed patients with COVID-19 was conducted by our team, in which, leflunomide resulted in beneficial virologic clearance and length of hospital stay [15]. Based on that background, we conducted a prospective randomized, controlled, open-label trial, to evaluate the efficacy and safety of oral leflunomide to treat hospitalized COVID-19 patients with prolonged post-symptomatic viral shedding.

METHODS

Patients
From March 10, 2020 to April 12, 2020, a total of 50 consecutive patients with confirmed COVID-19 with prolonged viral shedding were enrolled as study candidates. All patients were referred from other COVID-19 designated wards or makeshift (Fangcang) hospitals to the East Campus, Renmin Hospital of Wuhan University.
The inclusion criteria were as follows: (1) aged 18-70 years with a diagnosis of COVID-19 conforming to the Chinese Guidelines [16]; (2) hospitalized for prolonged post-symptomatic viral shedding; (3) able to orally take medication; (4) non-pregnant women; (5) effective contraception for 7 days after taking the last medication. Candidates were excluded based on the following: (1) presence of any condition that would not allow the protocol to be followed, including known allergy to leflunomide, use of medications that are contraindicated with leflunomide and that could not be replaced or stopped during the trial period; (2) pregnant or breast-feeding; (3) known other serious comorbidities, such as liver, cardiovascular, cerebrovascular diseases, severe renal insufficiency or advanced cancer; (5) had received interferon before enrollment; (6) unwilling to participate in the study.

Ethics approval and consent to participate
This clinical trial received approval from the Ethics Committee of the Renmin Hospital of Wuhan University (No.WDRY2020-K063) and written informed consent was obtained from each participant. The study was registered at the Chinese Clinical Trial Registry (ChiCTR 2000030058).

Trial design and study protocol
Patients were assessed for eligibility on the basis of the inclusion and exclusion criteria (Figure 1). At the first interview, each candidate completed a comprehensive questionnaire including demographics, comorbidities, initial-episode syndromes and disease severity at the first admission, length of virus shedding from onset to enrollment, duration of post-symptomatic viral shedding, antiviral medication before enrollment, etc. However, the original protocol had been amended, which was for a multicenter, randomized, double-blind, controlled clinical trial. Due to few new COVID-19 patients in Wuhan, China since early March 2020, only convalescing patients with prolonged post-symptomatic viral shedding rather than those in the acute stage were enrolled in single center, with a small sample size.

Fifty eligible patients were randomly assigned to a combination treatment group that received leflunomide (50 mg, q12h, three consecutive times, orally; then 20 mg, once a day for 8 days; a total course of 10 days) plus nebulized IFN α-2a (3 million IU each time, adding 2 ml of sterilized water, atomization inhalation twice daily for 10 days), or to a control group that received nebulized IFN α-2a alone for 10 days. Leflunomide tablets (10 mg per tablet) were produced by Long March-Xinkai Pharmaceutical Co., Ltd, Suzhou, China. Recombinant human IFN α-2a solution (3 million IU/ml) for nebulization was produced by 3SBIO Inc., Shenyang, China.

This was an open-label, prospective randomized, controlled trial, which was conducted at East Campus, Renmin Hospital of Wuhan University. The enrollment was initiated on March 10, 2020 and ended on April 12, 2020. The last patient studied was discharged on April 26, 2020 and was followed-up until May 25, 2020.
Criteria for prolonged post-symptomatic viral shedding
Since there is no standard definition, we adopted the following definition of COVID-19 patients with prolonged post-symptomatic viral shedding, which refers to laboratory confirmed patients with COVID-19 who continued to have nasopharyngeal RT-PCR positivity at least two weeks after symptom resolution and after their abnormal CT imaging improved significantly.

Measurement of virus shedding by RT-PCR
After enrollment, serial nasopharyngeal swab specimens were obtained at the baseline (before leflunomide or IFN α-2a was administered) and once every two days until nucleic acid tests were negative twice consecutively with an interval of ≥24 hours. RT-PCR for SARS-CoV-2 was performed using a commercial kit (GeneoDx Biotech Co., Ltd, Shanghai, China).

Clinical and laboratory monitoring
Clinical symptoms of patients were assessed once daily by trained nurses using diary cards, analysis of peripheral blood cells, biochemical indicators and chest imaging studies performed at the baseline, on day 3, one day after treatment and or one day before discharge for patients meeting discharge criteria within ten days of enrollment. Data were recorded on paper case record forms, then were entered into an electronic database and validated by the clinical trial staff.

Discharge criteria and follow-up after discharge
Discharge criteria were as follows [16]: having a normal temperature for >3 days, significant improvements of respiratory symptoms and CT imaging, nucleic acid tests negative twice consecutively with an interval of ≥24 hours. After discharge, the patients were isolated at a designated place for 14 days as recommended [16], which was arranged by community committees where the patients resided. They were followed-up by primary health-care facilities and were re-tested for viral nucleic acid on days 7 and 14. After that, they stayed in their homes for a second isolation period of 14 days, and were then retested for viral nucleic acid by the end of this quarantine period. We collected each patient’s medical information during the isolation, which was shared with permission. In our study, enrolled patients with five consecutively negative nucleic acid tests were considered as having “true negative” results (two times during hospitalization, two times during the first isolation, and one time at the end of the second quarantine). If any patient at any time-point had a positive test for SARS-CoV-2, they were sent to a designated site for isolation and medical observation.
Outcome measures
The primary end point was the duration of viral shedding, which was defined as the time from randomization to the first negative nucleic acid test of five consecutive RT-PCR results. Other clinical outcomes included clinical status, i.e. progressive rate to severe illness, syndromes, peripheral blood cells and biochemical parameters, C-reactive protein and inflammatory cytokines, length of hospital stay, etc. Safety outcomes included adverse events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.

Statistical analysis
Continuous variables are presented as medians (IQR). The normality of the distribution of variables was performed using the Kolmogorov-Smirnov test and statistical comparisons using a t-test. Categorical variables are expressed as absolute numbers or percentages and are compared by the χ² test, Fisher’s exact test or one-way ANOVA. The time to negative RT-PCR test was developed using the Kaplan-Meier method and was compared with a log-rank test. A P<0.05 was considered statistically significant. All statistical analyses were performed using SAS 9.4 software (SAS Institute Inc, Cary, NC).

RESULTS
The characteristics of the patients in this study are summarized in Tables 1 and 2. Of the 50 patients who underwent randomization and treatment assignment, 26 were assigned to the combination treatment group that orally received leflunomide plus nebulized IFN α-2a, and 24 were assigned to the control group that received nebulized IFN α-2a alone. In the combination treatment group, 24 patients (92.3%) received all treatments as assigned, but two patients did not complete the 10 day treatment regimen, one due to serious diarrhea 2 days after taking the drug, and the other due to impaired liver function. There were no significant differences in age [56.0 (43.0-67.3) vs 55.5 (47.8-66.5), P=0.836] or gender [13:11 vs 9:15 (M:F), P=0.274] between the combination treatment group and the control group. In addition, no significant differences were found between the two groups in terms of most first symptoms, disease severity at first admission, comorbidities, the use of anti-viral drugs, duration of post-symptomatic viral shedding or length from disease onset to enrollment [44.5 (30.0-47.8) vs. 44.0 (36.3-52.0) days, P=0.536]. Regarding the first symptoms, more cough and expectoration was found in the combination treatment group. However, the differences of initial symptoms did not influence the lengths of virus shedding between the two groups (Tables 1 and 3).

At enrollment, none of the patients in either group had a fever or respiratory symptoms, and none had obvious infiltrative lesions on pulmonary imaging. The median interval time between the
disappearance of symptoms and randomization was 26.0 days (IQR, 15.0 to 33.0 days) in the combination treatment group and 24.0 days (IQR, 17.0 to 32.0 days) in the control group (Table 1). There were no important between-group differences in baseline laboratory test results at enrollment, except for the level of creatine kinase in the control group, the level of tumor necrosis factor in the combination group was slightly higher, although both were within the normal range (Table 2).

Twenty-four of the 26 patients in the combination treatment group and all 24 patients in the control group completed this study and were discharged. No deaths or severe illness occurred and the illness severity was not worse in either group. In terms of the duration of viral shedding after treatment, patients assigned to the combination treatment group had a time to negative RT-PCR results that was not different from patients assigned to the control group (Figure 2), the median time was 8.0 (6.0-15.5) days and 11.5 (6.3-16.5) days, respectively, \( P=0.488 \). In addition, patients in the combination treatment group had a similar duration from randomization to hospital discharge as the control group (median, 29.0 days vs. 33.0 days; \( P=0.170 \)).

Laboratory examinations were conducted before and after treatment for all patients (Table 2). Of the post-treatment test results, there were no differences between the two groups except that the lymphocyte count in the control group was slightly higher than in the combination treatment group \([1.7 (1.1-2.3) \times 10^9/L \text{ vs. } 1.4 (1.0-1.7) \times 10^9/L, P=0.045]\).

In terms of comparison between pre- and post-treatment, the control group had a mild decrease after treatment in their levels of creatine kinase, urea, creatinine, LDH, fibrinogen, prothrombin time and APTT. In addition, the titration of IgM for SARS-Cov-2 was also lower \([10.9 (4.5-44.6) \text{ vs. } 4.4 (2.8-54.2), \text{AU/mL, } P=0.017]\). However, compared with pre-treatment, there was not a significant decrease in the levels of C-reactive protein or LDH in the combination treatment group after treatment. Further, the combination treatment group did not have significantly reduced levels of inflammatory cytokines, i.e. IL-2, IL-4, IL-6, IL-10, TNF or interferon-\(\gamma\). The titration of IgM for SARS-Cov-2 was also not changed much, although the creatine kinase level and the prothrombin time decreased.

For safety, a total of 10 patients in the combination treatment group and 4 in the control group reported adverse events (Table 3) but that was not significantly different between the two groups (41.7\% vs. 16.7\%, \( P=0.057 \)). There was one serious gastrointestinal adverse event that caused the discontinuation of treatment in the combination treatment group but none occurred in the control group, which was judged by the investigators to be related to the trial medication. For laboratory results, the absolute number of increased liver enzymes in the combination treatment group was higher than in the control group but was not statistically different (Table 2), although one patient in the combination treatment group discontinued treatment on day 3 due to liver enzymes (ALT 109 U/L, AST 51 U/L). Other obvious laboratory abnormalities were not observed.
DISCUSSION

This randomized trial found that leflunomide treatment added to nebulized IFN-α-2a was not associated with improvement of viral negative conversion in COVID-19 patients with prolonged post-symptomatic shedding, and the between-group difference in the median time to negative virus nucleic acid (median, 8.0 days vs. 11.5 days) was not significant.

Persistent viral shedding is a serious problem [17]. Cao and colleagues reported that SARS-CoV-2 RNA was detected in 40.7% of their patients on day 28 after a 14-day treatment regimen with lopinavir-ritonavir [18]. Another report showed that the median duration of viral shedding was 20 days in patients with COVID-19 and could be as long as 37 days [19]. An analysis of the transmission of COVID-19 revealed that 86% of subjects in China in January-February 2020 potentially contracted the virus from patients with no or minimal symptoms [20]. The prolonged existence of virus presents difficulties in attempts to control the community spread of SARS-CoV-2.

Partial in vitro studies or clinical trials have suggested the potential therapeutic activity of several compounds against coronaviruses [21], however, there are no specific antiviral pharmaceutical treatments available for patients with COVID-19 [22]. The results of those studies did not show clinical improvement or the clinical trial results were controversial, including lopinavir-ritonavir [18], remdesivir [23], favipiravir [24] and chloroquine or hydroxychloroquine [25].

We evaluated the efficacy and safety of leflunomide on SARS-CoV-2 infection in this study and compared it with the roles of interferon treatment alone. Interferon is recommended to be used for patients with COVID-19 by the Chinese guidelines [16], for it has broad-spectrum antiviral activity [26], has been widely used for the treatment of virus infections [26, 27, 28], and is also effective for treating patients with COVID-19 [29, 30]. Leflunomide is capable of inhibiting viral RNA genome replication and rescues mice from advanced influenza infections [12]. Leflunomide directly targets DHODH, the host’s de-novo pyrimidine synthesis enzyme, to cut off intercellular pyrimidine resources required as the starting step of building the viral RNA genome [12]. Like chloroquine and hydroxychloroquine, leflunomide has a dual mechanism of antiviral and immunoregulation and has been approved to treat arthritis for many years [31, 32]. Leflunomide has a clear-cut drug target of DHODH and has few off-target effects [33], whereas chloroquine and hydroxychloroquine are multi-targeted and have more severe adverse effects [34]. Therefore, DHODH inhibitors may be attractive drugs for treating acute and severe virus infection diseases [35]. In a preliminary trial, we found that leflunomide resulted in beneficial virologic clearance and length of hospital stay for patients with COVID-19 [15].
In the present study, the baseline characteristics of the patients at enrollment were generally balanced across the two groups that did not differ with regard to duration, severity of illness and majority baseline laboratory results. However, differences in the negative conversion of virus nucleic acid between the combination treatment group and the control group were not observed. As compared to treatment with nebulized IFN α-2a only, the combination of oral leflunomide and nebulized IFN α-2a did not significantly shorten the duration of viral shedding time or the duration from randomization to hospital discharge. The results indicate that leflunomide did not accelerate virus clearance in COVID-19 patients with prolonged positive nucleic acid testing. Remarkably, the combination therapy did not significantly reduce levels of C-reactive protein, LDH or inflammatory cytokines. The titration of IgM for SARS-Cov-2 was not changed much, although the level of creatine kinase and the prothrombin time decreased after treatment. In contrast, nebulized treatment with IFN α-2a only decreased the levels of creatine kinase, LDH, fibrinogen, prothrombin time, APTT and the titration of IgM for SARS-Cov-2.

For safety, two leflunomide recipients discontinued treatment due to gastrointestinal adverse events or abnormal liver function, however, there was no statistical difference in the total number of adverse events between the two groups. The side-effect profile observed in the current trial arouses concern about the use of higher or more prolonged leflunomide dose regimens in efforts to improve outcomes.

Our trial has several limitations. Particularly, the limited sample size, as well as the unblinded nature of the trial and the lack of a placebo were the main shortcomings. Due to the few new COVID-19 patients in Wuhan, China since early March 2020, convalescing patients rather than those in the acute stage were enrolled, which may cause a bias in evaluating the potential effectiveness of leflunomide on COVID-19 infections. The inhibition of DHODH may mainly hinder the activated, fast proliferating/replication of immune cells/viruses that require the de novo synthesis of pyrimidine bases, whereas resting cells are less affected since pyrimidine bases can be recruited by the salvage pathway [36]. However, the question of whether earlier leflunomide treatment of patients with acute COVID-19 could have clinical benefit is an important one that requires further studies. Because common antirheumatic drugs have not shown consistent antiviral effects as expected [37, 38], it is considered prudent to continue any ongoing immunosuppressive therapy [39].

Conclusions

Our data show that leflunomide did not shorten the number of virus clearance days or shorten the duration of stay in the hospital for COVID-19 patients with prolonged post-symptomatic shedding. With a larger sample, double-blinded and controlled design, future trials may help to clarify the antiviral efficacy and drug safety of leflunomide.
Contributors

M.M.W., Y.Z., W.H.H., D.Z., Y.T.Z., T.W., Z.S.Z., X.C.L. and S.L.Z. collected the epidemiological and clinical data. M.M.W., Y.Z. and W.H.H. were responsible for enrollment and clinical monitoring. Z.L.L., L.L. and Z.H.W were responsible for the distribution and storage of medicines. W.H.H. and D.Z. were responsible for statistical data. M.M.W., Y.Z and K.H. drafted the manuscript. K.H. was responsible for funding, study conception and design, revising and submitting the final manuscript.

Acknowledgments

We respectfully thank all patients enrolled in this study. This work was supported by the National Key Research and Development Plan for the Emergency Management of Novel Coronavirus Pneumonia, China (No.2020YFC0845100) and the Wuhan Municipal Key Technology Project on Novel Coronavirus Pneumonia, China (No.2020020101010005).

Role of the Funder/Sponsor

The funding agencies had no role in the study design and clinical medications; collection, analysis, and interpretation of the data; preparation, written, review, or approval of the manuscript.

Conflict of Interest Disclosures

Zhao Y and Hu WH contributed equally with Wang MM. The authors have no competing interest to declare for this study.
References

1. Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science 2020; Mar. 22. doi:10.1126/science.abb8497.

2. Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential antiviral drugs for SARS-Cov-2 treatment: preclinical findings and ongoing clinical research. In Vivo 2020; 34(3 Suppl):1597-602.

3. Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 2020; 22(2): 80-5.

4. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect 2020; 53(3):436-43.

5. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science 2020; 367(6485):1412-3.

6. Zhu H, Fu L, Jin Y, Shao J, Zhang S, Zheng N, et al. Clinical features of COVID-19 convalescent patients with re-positive nucleic acid detection. J Clin Lab Anal 2020; Jun 7; e23392.

7. Wong J, Koh WC, Momin RN, Alikhan M, Fadillah N, Naing L. Probable causes and risk factors for positive SARS-CoV-2 test in recovered patients: evidence from Brunei Darussalam. J Med Virol 2020; Jun 19;10.1002/jmv.26199. doi: 10.1002/jmv.26199.

8. Kang YJ. South Korea’s COVID-19 Infection Status: From the perspective of re-positive test results after viral clearance evidenced by negative test results. Disaster Med Public Health Prep 2020; May 22; 1-3. doi: 10.1017/dmp.2020.168.

9. Hoang VT, Dao TL, Gautret P. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. J Med Virol 2020; May 25: 10.1002/jmv.26056. doi: 10.1002/jmv.26056.

10. Zhang WY, Yu LQ, Huang JA, Zeng DX. Prolonged viral RNA shedding duration in COVID-19. Am J Ther 2020; Jun 1: 10.1097/MJT.000000000001200. doi: 10.1097/MJT.000000000001200.

11. Yuan J, Kou S, Liang Y, Zeng JF, Pan Y, Liu L. PCR assays turned positive in 25 discharged COVID-19 Patients. Clin Infect Dis 2020; Apr 8; ciaa398. doi: 10.1093/cid/ciaa398.

12. Xiong R, Zhang L, Li S, Sun Y, Ding M, Wang Y, et al. Novel and potent inhibitors targeting DHODH are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2. Protein Cell. 2020 Aug 4:1-17. doi: 10.1007/s13238-020-00768-w. (Online ahead of print)

13. Fragoso YD, Brooks JBB. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol 2015; 8(3):315-20.

14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497-506.
15. Hu K, Wang M, Zhao Y, Zhang Y, Wang T, Zheng Z, et al. A small-scale medication of Leflunomide as a treatment of COVID-19 in an open-label blank-controlled clinical trial. Virol Sin 2020; 21:1-9.
16. (Released by National Health Commission & National Administration of Traditional Chinese Medicine on March 3, 2020). Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J 2020; 133(9):1087-95.
17. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J 2020; 133(9):1039-43.
18. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382(19):1787-99.
19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054-62.
20. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020; 368(6490):489-93.
21. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3):269-71.
22. Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 2020; 9(2):575.
23. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236):1569-78.
24. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020; Mar 18. doi: 10.1016/j.eng.2020.03.007.
25. Chowdhury MS, Rathod J, Gernsheimer J. A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. Acad Emerg Med 2020; 27(6):493-504.
26. Chan JFW, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212(12):1904-13.
27. Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, et al; BC Hepatitis Testers Cohort Team. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. J Hepatol 2019; 71(6):1116-25.
28. Bourke NM, Napoletano S, Bannan C, Ahmed S, Bergin C, McKnight Á, et al. Control of HIV infection by IFN-alpha: implications for latency and a cure. Cell Mol Life Sci 2018; 75(5):775-83.

29. Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-α2b treatment for COVID-19. Front Immunol 2020; 11:1061.

30. Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020; 395(10238):1695-704.

31. Tlustochowicz ME, Kisiel B, Tlustochowicz W. Quality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in therapeutic program: a retrospective analysis of data from the PLUS study. Adv Clin Exp Med 2019; 28(11):1545-53.

32. Wiese MD, Hopkins AM, King C, Wechalekar MD, Lee A, Spargo L, et al. Precision medicine with leflunomide: consideration of DHODH haplotype and plasma teriflunomide concentration can substantially modify outcomes in patients with rheumatoid arthritis. Arthritis Care Res 2020; Apr 27. doi: 10.1002/acr.24236.

33. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59(11):841-9.

34. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020; 16(3):155-66.

35. Fragoso YD, Brooks JB. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol 2015; 8(3):315-20.

36. Singh A, Maqbool M, Mobashir M, Hoda N. Dihydroorotate dehydrogenase: a drug target for the development of antimalarials. Eur J Med Chem 2017; 125:640-51.

37. Cai S, Sun W, Li M, Dong L. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. Clin Rheumatol 2020; Jun 19;1-6. doi: 10.1007/s10067-020-05234-w.

38. Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis 2020; May 22:annrheumdis-2020-217627.

39. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020; 39(7):2055-62.
Legends

Table 1  Demographics, first-episode syndromes and comorbidities in patients with confirmed COVID-19 at the first admission [Median (IQR) or n]

# Lianhua Qingwen capsule is a kind of Chinese traditional medicine and is recommended for patients with COVID-19 [16].

Combination group: leflunomide plus IFN α-2a; Control group: IFN α-2a alone.

Table 2  Laboratory results of patients with COVID-19 at enrollment and after treatment [Median (IQR) or n]

Combination group: leflunomide plus IFN α-2a; Control group: IFN α-2a alone.

WBC = White blood cell count; N = Neutrophil count; L = Lymphocyte count; CRP = C-reactive protein; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; LDH = Lactate dehydrogenase; Ultra-TnI = Ultratroponin I; APTT = activated partial thromboplastin time; IL = Interleukin; TNF = tumor necrosis factor.
a: Comparison of baseline data between the two groups.
b: Data comparison between after treatment the two groups.

Table 3  Outcomes and adverse events of patients with COVID-19 after enrollment [Median (IQR) or n]

Combination group: leflunomide plus IFN α-2a; Control group: IFN α-2a alone.

Figure 1. Study flow chart.

Figure 2. Kaplan–Meier curve showing time to negative test for patients who were treated with leflunomide and patients who were treated with interferon-α only.

Compared with interferon α-2a nebulized therapy, oral leflunomide did not significantly shorten the time of virus shedding in patients with SARS-Cov-2 infection (hazard ratio for negative RT-PCR 0.70; 95% confidence interval [CI], 0.391-1.256; P=0.186).

Combination group: leflunomide plus IFN α-2a; Control group: IFN α-2a alone.
| Parameters                                                                 | Combination group (N=24) | Control group (N=24) | P value |
|---------------------------------------------------------------------------|--------------------------|----------------------|---------|
| **Demographics**                                                          |                          |                      |         |
| Age                                                                       | 56.0 (43.0-67.3)         | 55.5 (47.8-66.5)     | 0.836   |
| Sex (M:F)                                                                 | 13:11                    | 9:15                 | 0.274   |
| **First symptoms**                                                        |                          |                      |         |
| Fever (T ≥37.0°C), n (%)                                                  | 18 (75.0)                | 17 (70.8)            | 0.745   |
| Tmax, ℃ (IQR)                                                            | 38.0 (37.0-38.9)         | 38.3 (37.0-38.6)     | 0.741   |
| Cough, n (%)                                                             | 17 (70.8)                | 8 (33.3)             | 0.009   |
| Expectoration, n (%)                                                      | 8 (33.3)                 | 2 (8.3)              | 0.033   |
| Chest tightness, n (%)                                                    | 7 (29.2)                 | 7 (29.2)             | 1.000   |
| Fatigue, n (%)                                                            | 8 (33.3)                 | 10 (41.7)            | 0.551   |
| Myalgia, n (%)                                                            | 6 (25.0)                 | 2 (8.3)              | 0.245   |
| Nausea, n (%)                                                             | 0 (0)                    | 1 (4.2)              | 1.000   |
| Vomiting, n (%)                                                           | 0 (0)                    | 2 (8.3)              | 0.470   |
| Diarrhea, n (%)                                                           | 1 (4.2)                  | 2 (8.3)              | 1.000   |
| Poor appetite, n (%)                                                      | 4 (16.7)                 | 1 (4.2)              | 0.345   |
| **Severity on first admission**                                           |                          |                      |         |
| Mild, n (%)                                                               | 11 (45.8)                | 10 (41.7)            | 0.979   |
| Moderate, n (%)                                                           | 9 (37.5)                 | 9 (37.5)             |         |
| Severe, n (%)                                                             | 3 (12.5)                 | 4 (16.7)             |         |
| Critical, n (%)                                                           | 1 (4.2)                  | 1 (4.2)              |         |
| **Comorbidity**                                                           |                          |                      |         |
| Hypertension, n (%)                                                       | 7 (29.2)                 | 5 (20.8)             | 0.505   |
| Diabetes, n (%)                                                           | 0 (0)                    | 2 (8.4)              | 0.470   |
| Coronary artery disease, n (%)                                            | 1 (4.2)                  | 0 (0)                | 1.000   |
| Chronic obstructive pulmonary disease, n (%)                              | 1 (4.2)                  | 1 (4.2)              | 1.000   |
| Malignancy, n (%)                                                         | 1 (4.2)                  | 0 (0)                | 1.000   |
| Chronic liver disease, n (%)                                              | 1 (4.2)                  | 0 (0)                | 1.000   |
| **Length of virus shedding from onset to enrollment, day**                |                          |                      |         |
|                                                                          | 44.5 (30.0-47.8)         | 44.0 (36.3-52.0)     | 0.536   |
| Patients with initial cough and expectoration, day                         | 54 (50.0-61.0)           | 42.0 (41.0-53.8)     | 0.096   |
| Duration of post-symptomatic virus shedding, day | 26.0 (15.0-33.0) | 24.0 (17.0-32.0) | 0.549 |
|-----------------------------------------------|------------------|------------------|-------|
| Patients with initial cough and expectoration, day | 18.5 (11.0-23.25) | 30.0 (9.5-37.5) | 0.116 |

### Anti-viral drugs before enrollment

| Drug                          | Combination | Control | p-value |
|-------------------------------|-------------|---------|---------|
| Lopinavir - Ritonavir, n (%)  | 1 (4.2)     | 4 (16.7) | 0.345   |
| Arbidol Hydrochloride, n (%)  | 17 (70.8)   | 16 (66.7) | 0.755   |
| Oseletamivir, n (%)           | 4 (16.7)    | 3 (12.5)  | 1.000   |
| Ribavirin, n (%)              | 7 (29.2)    | 9 (37.5)  | 0.540   |
| Lianhua Qingwen capsule, n (%)| 14 (58.3)   | 14 (58.3) | 1.000   |
| Hydroxychloroquine, n (%)     | 12 (50.0)   | 13 (54.2) | 0.773   |
| Thymosin Alph-1enteric coated tablet, n (%) | 14 (58.3) | 14 (58.3) | 1.000   |
| Immunoglobulin, n (%)         | 3 (12.5)    | 6 (25.0)  | 0.460   |
| Glucocorticoid, n (%)         | 8 (33.3)    | 7 (29.2)  | 0.755   |
| Antibiotics, n (%)            | 16 (66.7)   | 12 (50.0) | 0.242   |

**Combination group:** leflunomide plus IFN α-2a. **Control group:** IFN α-2a alone.

※ Length of virus shedding from onset to enrollment in patients with initial cough and expectoration.

※※ Patients with initial cough and expectoration in patients with initial cough and expectoration.

# Lianhua Qingwen capsule is a kind of Chinese traditional medicine and is recommended for patients with COVID-19 [16].
### Table 2: Laboratory results of patients with COVID-19 at enrollment and after treatment [Median (IQR) or n]

| Parameters | Combination group [n=24, Median (IQR) or n] | Control group [n=24, Median (IQR) or n] | P-value (Baseline vs After treatment) | P-value (Baseline vs After treatment) |
|------------|---------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| WBC (3.5-9.5 10^3/L) | 5.0 (4.3-6.6) | 5.9 (4.2-7.8) | 0.122 | 5.6 (4.7-7.3) | 0.072 |
| WBC >4.0 | 4 (26.7) | 3 (20.8) | 1.000 | 4 (26.7) | 3 (12.5) | 1.000 |
| N (1.8-6.5 10^3/L) | 2.8 (2.3-3.9) | 3.9 (2.0-5.5) | 0.131 | 3.1 (2.5-4.4) | 0.194 |
| L (1.3-3.2 10^7/L) | 1.5 (0.9-1.7) | 1.4 (1.0-1.7) | 0.889 | 1.5 (1.0-2.0) | 0.093 |
| Hemoglobin (130 - 175 g/L) | 123.5 (114.8-144.0) | 127.0 (118.1-137.0) | 0.976 | 123.0 (109.5-146.8) | 0.574 |
| Platelet count (125-350 10^9/L) | 201.5 (177.0-214.0) | 201.0 (168.0-252.0) | 0.888 | 206.5 (148.9-258.3) | 0.663 |
| CRP (0-10 mg/L) | 5.0 (5.0-11.1) | 5.0 (5.0-12.0) | 0.463 | 8.6 (5.0-18.4) | 0.064 |
| Albumin (40-55 g/L) | 41.9 (38.5-42.8) | 41.1 (38.2-41.1) | 0.882 | 42.4 (38.3-44.8) | 0.061 |
| ALT (9-50 U/L) | 23.5 (15.5-35.5) | 27.0 (16.0-86.5) | 0.122 | 28.5 (18.3-53.0) | 0.679 |
| AST (15-40 U/L) | 22.5 (18.0-32.3) | 22.0 (18.0-31.5) | 0.163 | 26.0 (17.3-38.0) | 0.289 |
| Alkaline phosphatase (40-125 U/L) | 65.5 (66.3-73.4) | 66.0 (68.9-85.5) | 0.867 | 65.5 (45.1-77.5) | 0.554 |
| Bilirubin (0-23 mmol/L) | 12.6 (9.9-15.8) | 12.5 (10.2-17.1) | 0.322 | 10.1 (7.0-14.5) | 0.136 |
| Potassium (3.5 - 5.3 mmol/L) | 4.0 (3.6-4.2) | 4.0 (3.4-4.2) | 0.189 | 3.8 (3.4-4.2) | 0.139 |
| Sodium (137 - 147 mmol/L) | 140.0 (136.9-144.0) | 141.5 (138.5-154.0) | 0.185 | 140.0 (137.0-144.0) | 0.081 |
| Urea (3.8 - 9.5 mmol/L) | 4.1 (4.2-4.8) | 4.8 (4.2-5.7) | 0.839 | 5.5 (4.5-6.1) | 0.002 |
| Creatinine (57-111 jmoles/L) | 33.0 (28.5-37.5) | 34.0 (27.0-47.0) | 0.088 | 32.0 (40.0-66.3) | 0.003 |
| Creatine kinase (138-198 U/L) | 57.5 (53.8-76.5) | 59.0 (27.3-58.3) | 0.019 | 56.5 (49.3-119.5) | 0.007 |
| LDH (120 - 250 U/L) | 195.0 (167.0-233.8) | 195.5 (172.8-232.8) | 0.156 | 210.0 (171.0-285.5) | 0.009 |
| Leu-a-Tub (0.04 mg/dL) | 0.006 (0.006-0.006) | 0.006 (0.006-0.006) | 1.000 | 0.006 (0.006-0.007) | 0.856 |
| D-dimer (0-0.55 mg/L) | 0.4 (0.2-0.7) | 0.3 (0.2-0.7) | 0.206 | 0.4 (0.2-1.4) | 0.865 |
| Fibrinogen (2 - 4 g/ dl) | 2.8 (2.3-3.2) | 2.9 (2.3-3.2) | 0.073 | 3.1 (2.7-3.4) | 0.048 |
| Prothrombin time (9 - 13 s) | 11.2 (10.9-12.0) | 11.2 (10.8-11.8) | 0.042 | 11.1 (10.8-12.3) | 0.012 |
| APPT (25 - 31 s) | 27.0 (25.1-29.0) | 26.7 (24.9-28.8) | 0.953 | 27.9 (25.4-30.3) | 0.003 |
| D-2 (0.14 pg/ml) | 3.6 (3.3-3.8) | 3.8 (3.5-3.8) | 0.799 | 3.5 (3.2-3.7) | 0.246 |
| IL-6 (12.9 pg/ml) | 3.1 (2.9-3.4) | 3.0 (2.8-3.4) | 0.533 | 3.2 (2.7-3.4) | 0.435 |
| IL-10 (0.9 pg/ml) | 6.0 (4.8-17.2) | 6.4 (5.2-8.8) | 0.861 | 6.0 (4.3-13.6) | 0.075 |
| IL-10 (5.9 pg/ml) | 5.9 (0.7-7.3) | 6.1 (5.4-8.4) | 0.721 | 5.7 (4.9-6.3) | 0.477 |

Note: P-values indicate the statistical significance of changes from baseline to after treatment.
| Combination group: leflunomide plus IFN α-2a; Control group: IFN α-2a alone. |  |  |  |  |  |  
|---|---|---|---|---|---|---|
| **WBC** |  |  |  |  |  |  
| White blood cell count; **N** = Neutrophil count; **L** = Lymphocyte count; **CRP** = C-reactive protein; **ALT** = Alanine aminotransferase; **AST** = Aspartate aminotransferase; **LDH** = Lactate dehydrogenase; **Ultra-TnI** = Ultratroponin I; **APTT** = activated partial thromboplastin time; **IL** = Interleukin; **TNF** = tumor necrosis factor. | a: Comparison of baseline data between the two groups. | b: Data comparison between after treatment the two groups. |
Table 3 Outcomes and adverse events in patients with COVID-19 after enrollment [Median (IQR) or n]  

| Parameters                                      | Combination group (N=24) | Control group (N=24) | P value |
|-------------------------------------------------|--------------------------|----------------------|---------|
| Duration of treatment, day                      | 10.0 (7.0-12.0)          | 10 (7.0-12.0)        | 1.000   |
| Conversion to severe case after enrollment, n (%)| 0 (0)                    | 0 (0)                | -       |
| Death after enrollment, n (%)                   | 0 (0)                    | 0 (0)                | -       |
| Duration of viral shedding after enrollment, day| 8.0 (6.0-15.5)           | 11.5 (6.3-16.5)      | 0.488   |
| Patients with initial cough and expectoration, day※ | 11.0 (7.0-16.0)          | 16.0 (7.5-38.8)      | 0.559   |
| Length of hospital stay, day                    | 29.0 (19.3-47.3)         | 33.0 (29.3-42.8)     | 0.170   |
| Side effects after enrollment, n (%)            | 10 (41.7)                | 4 (16.7)             | 0.057   |
| Symptoms                                        |                          |                      |         |
| Nausea, n (%)                                   | 2 (8.3)                  | 1 (4.2)              | 1.000   |
| Vomiting, n (%)                                 | 1 (4.2)                  | 1 (4.2)              | 1.000   |
| Diarrhea, n (%)                                 | 0 (0)                    | 1 (4.2)              | 1.000   |
| Stomach ache, n (%)                             | 1 (4.2)                  | 0 (0)                | 1.000   |
| Dry mouth, n (%)                                | 1 (4.2)                  | 0 (0)                | 1.000   |
| Chest tightness, n (%)                          | 2 (8.3)                  | 0 (0)                | 0.470   |
| Palpitations, n (%)                             | 1 (4.2)                  | 1 (4.2)              | 1.000   |
| Insomnia or sleep disturbances, n (%)           | 2 (8.3)                  | 1 (4.2)              | 1.000   |
| Abnormal laboratory results                     |                          |                      |         |
| Leukopenia, n (%)                               | 1 (4.2)                  | 1 (4.2)              | 1.000   |
| Lymphopenia, n (%)                              | 2 (8.3)                  | 0 (0)                | 0.470   |
| Thrombocytopenia, n (%)                         | 1 (4.2)                  | 1 (4.2)              | 1.000   |
| Anemia, n (%)                                   | 3 (12.5)                 | 1 (4.2)              | 0.602   |
| Increased AST, n (%)                            | 3 (12.5)                 | 0 (0)                | 0.233   |
| Increased ALT, n (%)                            | 7 (29.2)                 | 1 (4.2)              | 0.053   |
| Hypoalbuminemia, n (%)                          | 1 (4.2)                  | 0 (0)                | 1.000   |

Combination group: leflunomide plus IFN α-2a; Control group: IFN α-2a alone.

※ Duration of viral shedding after enrollment in patients with initial cough and expectoration.
Figure 1

Assessed for eligibility (n=50)

Excluded (n=0)
- Not meeting inclusion criteria (n=0)
- Declined to participate (n=0)
- Other reasons (n=0)

Randomized (n=50)

Combination treatment group (n=26)
- Leflunomide plus nebulized IFN-α-2a (n=26)

Lost to follow-up (n=0)
Discontinued intervention (n=2)
- 1 had serious diarrhea
- 1 due to impaired liver function

Analysed (n=24)
- Excluded from analysis (n=0)

Control group (n=24)
- Nebulized IFN-α-2a alone (n=24)

Lost to follow-up (n=0)
Discontinued intervention (n=0)

Analysed (n=24)
- Excluded from analysis (n=0)
Figure 2

No. at risk
Combination group 24  23  12  8  3  0
Control group     24  20  15 10  6  4  2  2